Provided by Tiger Trade Technology Pte. Ltd.

Pulse Biosciences

20.75
+7.0651.57%
Post-market: 21.901.15+5.54%19:59 EST
Volume:2.84M
Turnover:54.90M
Market Cap:1.41B
PE:-18.32
High:20.80
Open:14.95
Low:14.61
Close:13.69
52wk High:22.75
52wk Low:12.56
Shares:67.77M
Float Shares:17.44M
Volume Ratio:11.47
T/O Rate:16.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1329
EPS(LYR):-0.9176
ROE:-86.99%
ROA:-48.90%
PB:15.17
PE(LYR):-22.61

Loading ...

Pulse Biosciences Inc. Files Initial Beneficial Ownership Statement for Director Maria Sainz

Reuters
·
6 hours ago

Top Midday Gainers

MT Newswires Live
·
14 hours ago

Sector Update: Health Care Stocks Rise in Afternoon Trading

MT Newswires Live
·
14 hours ago

Pulse Biosciences Reports Strong nPulse Atrial Fibrillation Study Results

TIPRANKS
·
Yesterday

Pulse Biosciences präsentiert erfolgreiche Studiendaten zum nPulse Cardiac Catheter System bei Vorhofflimmern

Reuters
·
Yesterday

Pulse Biosciences Inc. hat eine Aktualisierung ihres Finanzkalenders veröffentlicht

Reuters
·
Feb 05

Pulse Biosciences Reports Positive 12-Month Data for Nanosecond PFA Catheter in Atrial Fibrillation Study

Reuters
·
Feb 03

Mizuho Securities Initiates Coverage on Pulse Biosciences With Outperform Rating

MT Newswires Live
·
Jan 30

Pulse Biosciences Inc : Mizuho Initiates Coverage With Outperform Rating; Target Price $25

THOMSON REUTERS
·
Jan 30

Pulse Biosciences initiated with an Outperform at Mizuho

TIPRANKS
·
Jan 30

New Cardiac Ablation Data and Board Appointment Might Change The Case For Investing In Pulse Biosciences (PLSE)

Simply Wall St.
·
Jan 13

Assessing Pulse Biosciences (PLSE) Valuation After Upcoming nPulse Cardiac Study Data Presentation

Simply Wall St.
·
Jan 09

Pulse Biosciences Appoints Maria Sainz to Board of Directors

Reuters
·
Jan 09

Pulse Biosciences Unveils Late-Breaking Data from nPulse Cardiac Catheter Study at AF Symposium

Reuters
·
Jan 06

Pulse Biosciences to Present at J.P. Morgan Healthcare Conference

Reuters
·
Dec 30, 2025

Why Pulse Biosciences (PLSE) Is Up 8.0% After FDA Clears Pivotal Atrial Fibrillation Trial

Simply Wall St.
·
Dec 23, 2025

BRIEF-Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Dec 20, 2025

Pulse Biosciences Grants Inducement Stock Options to New Employees

Reuters
·
Dec 20, 2025

Pulse Biosciences Wins FDA IDE Approval for nPulse Cardiac Catheter Study

Reuters
·
Dec 18, 2025

Pulse Biosciences Announces FDA Ide Approval to Initiate Its Npulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation

THOMSON REUTERS
·
Dec 18, 2025